Research ExplorerPublicationsDifferential effect on different immune subsets of neoadjuva...

Differential effect on different immune subsets of neoadjuvant chemotherapy in patients with TNBC

Standard

Differential effect on different immune subsets of neoadjuvant chemotherapy in patients with TNBC. / Massa, Chiara; Karn, Thomas; Denkert, Carsten; Schneeweiss, Andreas; Hanusch, Claus; Blohmer, Jens-Uwe; Zahm, Dirk-Michael; Jackisch, Christian; van Mackelenbergh, Marion; Thomalla, Jörg; Marme, Frederik; Huober, Jens; Müller, Volkmar; Schem, Christian; Mueller, Anja; Stickeler, Elmar; Biehl, Katharina; Fasching, Peter A; Untch, Michael; Loibl, Sibylle; Weber, Karsten; Seliger, Barbara.

In: J IMMUNOTHER CANCER, Vol. 8, No. 2, 11.2020.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Massa, C, Karn, T, Denkert, C, Schneeweiss, A, Hanusch, C, Blohmer, J-U, Zahm, D-M, Jackisch, C, van Mackelenbergh, M, Thomalla, J, Marme, F, Huober, J, Müller, V, Schem, C, Mueller, A, Stickeler, E, Biehl, K, Fasching, PA, Untch, M, Loibl, S, Weber, K & Seliger, B 2020, 'Differential effect on different immune subsets of neoadjuvant chemotherapy in patients with TNBC', J IMMUNOTHER CANCER, vol. 8, no. 2. https://doi.org/10.1136/jitc-2020-001261

APA

Massa, C., Karn, T., Denkert, C., Schneeweiss, A., Hanusch, C., Blohmer, J-U., Zahm, D-M., Jackisch, C., van Mackelenbergh, M., Thomalla, J., Marme, F., Huober, J., Müller, V., Schem, C., Mueller, A., Stickeler, E., Biehl, K., Fasching, P. A., Untch, M., ... Seliger, B. (2020). Differential effect on different immune subsets of neoadjuvant chemotherapy in patients with TNBC. J IMMUNOTHER CANCER, 8(2). https://doi.org/10.1136/jitc-2020-001261

Vancouver

Massa C, Karn T, Denkert C, Schneeweiss A, Hanusch C, Blohmer J-U et al. Differential effect on different immune subsets of neoadjuvant chemotherapy in patients with TNBC. J IMMUNOTHER CANCER. 2020 Nov;8(2). https://doi.org/10.1136/jitc-2020-001261

Bibtex

@article{1fd3e303cc2e47ad99f5216b1e2d97cd,
title = "Differential effect on different immune subsets of neoadjuvant chemotherapy in patients with TNBC",
abstract = "BACKGROUND: Triple-negative breast cancer (TNBC) is the most aggressive form of breast cancer (BC). Due to the absence of targets such as HER2 or hormone receptors, early TNBC is treated with surgery and chemotherapy. Since TNBC is also considered the most immunogenic type of BC with tumor infiltrating lymphocytes that are predictive for chemotherapy response and prognostic for patients' survival, many different immunotherapeutic strategies are currently explored in clinical trials for the treatment of this disease. In order to efficiently combine chemotherapy with immunotherapy, it is important to evaluate the effect of chemotherapy on immune cells in vivo.METHODS: Peripheral blood was taken from 56 patients with TNBC undergoing neoadjuvant chemotherapy with nanoparticle albumin-bound paclitaxel (Nab-Pac) followed by epirubicin and cyclophosphamide (EC) at three different time points. Multicolor flow cytometry was used to characterize the immune cell composition and functional properties along neoadjuvant chemotherapy.RESULTS: Whereas the first phase of the neoadjuvant chemotherapy did not significantly alter the patients' immune cell composition, after the second phase of chemotherapeutic administration most B cells (>90%) were lost and the frequency of natural killer (NK) cells and CD4+ T lymphocytes decreased approximately to 50%. In contrast, the frequency of CD8+ T cells were less affected.CONCLUSIONS: Despite late consequences of Nab-Pac cannot be ruled out, these data suggest that different chemotherapeutics might have distinct effects on the immune cell repertoire and that different immune cell populations exhibit a specific susceptibility to these chemotherapies with B and NK cells being more affected than T cells. This might also have an impact on the combination of chemotherapies with immunotherapies.TRIAL REGISTRATION NUMBER: NCT02685059.",
author = "Chiara Massa and Thomas Karn and Carsten Denkert and Andreas Schneeweiss and Claus Hanusch and Jens-Uwe Blohmer and Dirk-Michael Zahm and Christian Jackisch and {van Mackelenbergh}, Marion and J{\"o}rg Thomalla and Frederik Marme and Jens Huober and Volkmar M{\"u}ller and Christian Schem and Anja Mueller and Elmar Stickeler and Katharina Biehl and Fasching, {Peter A} and Michael Untch and Sibylle Loibl and Karsten Weber and Barbara Seliger",
note = "{\textcopyright} Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.",
year = "2020",
month = nov,
doi = "10.1136/jitc-2020-001261",
language = "English",
volume = "8",
journal = "J IMMUNOTHER CANCER",
issn = "2051-1426",
publisher = "BioMed Central Ltd.",
number = "2",

}

RIS

TY - JOUR

T1 - Differential effect on different immune subsets of neoadjuvant chemotherapy in patients with TNBC

AU - Massa, Chiara

AU - Karn, Thomas

AU - Denkert, Carsten

AU - Schneeweiss, Andreas

AU - Hanusch, Claus

AU - Blohmer, Jens-Uwe

AU - Zahm, Dirk-Michael

AU - Jackisch, Christian

AU - van Mackelenbergh, Marion

AU - Thomalla, Jörg

AU - Marme, Frederik

AU - Huober, Jens

AU - Müller, Volkmar

AU - Schem, Christian

AU - Mueller, Anja

AU - Stickeler, Elmar

AU - Biehl, Katharina

AU - Fasching, Peter A

AU - Untch, Michael

AU - Loibl, Sibylle

AU - Weber, Karsten

AU - Seliger, Barbara

N1 - © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

PY - 2020/11

Y1 - 2020/11

N2 - BACKGROUND: Triple-negative breast cancer (TNBC) is the most aggressive form of breast cancer (BC). Due to the absence of targets such as HER2 or hormone receptors, early TNBC is treated with surgery and chemotherapy. Since TNBC is also considered the most immunogenic type of BC with tumor infiltrating lymphocytes that are predictive for chemotherapy response and prognostic for patients' survival, many different immunotherapeutic strategies are currently explored in clinical trials for the treatment of this disease. In order to efficiently combine chemotherapy with immunotherapy, it is important to evaluate the effect of chemotherapy on immune cells in vivo.METHODS: Peripheral blood was taken from 56 patients with TNBC undergoing neoadjuvant chemotherapy with nanoparticle albumin-bound paclitaxel (Nab-Pac) followed by epirubicin and cyclophosphamide (EC) at three different time points. Multicolor flow cytometry was used to characterize the immune cell composition and functional properties along neoadjuvant chemotherapy.RESULTS: Whereas the first phase of the neoadjuvant chemotherapy did not significantly alter the patients' immune cell composition, after the second phase of chemotherapeutic administration most B cells (>90%) were lost and the frequency of natural killer (NK) cells and CD4+ T lymphocytes decreased approximately to 50%. In contrast, the frequency of CD8+ T cells were less affected.CONCLUSIONS: Despite late consequences of Nab-Pac cannot be ruled out, these data suggest that different chemotherapeutics might have distinct effects on the immune cell repertoire and that different immune cell populations exhibit a specific susceptibility to these chemotherapies with B and NK cells being more affected than T cells. This might also have an impact on the combination of chemotherapies with immunotherapies.TRIAL REGISTRATION NUMBER: NCT02685059.

AB - BACKGROUND: Triple-negative breast cancer (TNBC) is the most aggressive form of breast cancer (BC). Due to the absence of targets such as HER2 or hormone receptors, early TNBC is treated with surgery and chemotherapy. Since TNBC is also considered the most immunogenic type of BC with tumor infiltrating lymphocytes that are predictive for chemotherapy response and prognostic for patients' survival, many different immunotherapeutic strategies are currently explored in clinical trials for the treatment of this disease. In order to efficiently combine chemotherapy with immunotherapy, it is important to evaluate the effect of chemotherapy on immune cells in vivo.METHODS: Peripheral blood was taken from 56 patients with TNBC undergoing neoadjuvant chemotherapy with nanoparticle albumin-bound paclitaxel (Nab-Pac) followed by epirubicin and cyclophosphamide (EC) at three different time points. Multicolor flow cytometry was used to characterize the immune cell composition and functional properties along neoadjuvant chemotherapy.RESULTS: Whereas the first phase of the neoadjuvant chemotherapy did not significantly alter the patients' immune cell composition, after the second phase of chemotherapeutic administration most B cells (>90%) were lost and the frequency of natural killer (NK) cells and CD4+ T lymphocytes decreased approximately to 50%. In contrast, the frequency of CD8+ T cells were less affected.CONCLUSIONS: Despite late consequences of Nab-Pac cannot be ruled out, these data suggest that different chemotherapeutics might have distinct effects on the immune cell repertoire and that different immune cell populations exhibit a specific susceptibility to these chemotherapies with B and NK cells being more affected than T cells. This might also have an impact on the combination of chemotherapies with immunotherapies.TRIAL REGISTRATION NUMBER: NCT02685059.

U2 - 10.1136/jitc-2020-001261

DO - 10.1136/jitc-2020-001261

M3 - SCORING: Journal article

C2 - 33199511

VL - 8

JO - J IMMUNOTHER CANCER

JF - J IMMUNOTHER CANCER

SN - 2051-1426

IS - 2

ER -